research
Young Blood Stem Cells Showed the Wear of Age
Sickle cell disease pushed patient stem cells toward senescence, while two approved senolytics restored blood formation in models.
Summary
Sickle cell disease pushed patient stem cells toward senescence, while two approved senolytics restored blood formation in models.
St. Jude researchers found aging-associated features in blood stem cells from patients ages 6 to 23 with sickle cell disease. In mouse models carrying patient cells, senolytic treatment reduced senescence markers and improved blood formation; dasatinib plus quercetin produced similar model results. The work may inform stem-cell collection for gene therapy, but it is preclinical and does not establish a treatment regimen for patients.
Why it matters
Sickle cell disease pushed patient stem cells toward senescence, while two approved senolytics restored blood formation in models.
Limits and context
- The work may inform stem-cell collection for gene therapy, but it is preclinical and does not establish a treatment regimen for patients.
Key claims
Sickle cell disease pushed patient stem cells toward senescence, while two approved senolytics restored blood formation in models.
Qualification: The work may inform stem-cell collection for gene therapy, but it is preclinical and does not establish a treatment regimen for patients.
Evidence: source-2026-07-23-004
Sources
- St. Jude via Newswise: Sickle cell stem-cell agingSt. Jude Children's Research Hospital via Newswise · secondary reporting
Corrections
No corrections have been recorded for this story.